ATRC Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 1.25% compared to AtriCure, Inc.'s net margin of 12.68%. AtriCure, Inc.'s return on equity of -2.44% beat Boston Scientific Corp.'s return on equity of 12.55%.

AtriCure, Inc. has a consensus price target of $48.78, signalling upside risk potential of 50.64%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 38.34%. Given that AtriCure, Inc. has higher upside potential than Boston Scientific Corp., analysts believe AtriCure, Inc. is more attractive than Boston Scientific Corp..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $140.5M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. AtriCure, Inc.'s net income of $1.8M is lower than Boston Scientific Corp.'s net income of $670M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 2.89x versus 5.64x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Holdings, Inc. has a net margin of 1.25% compared to AtriCure, Inc.'s net margin of -2.7%. AtriCure, Inc.'s return on equity of -2.44% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.

AtriCure, Inc. has a consensus price target of $48.78, signalling upside risk potential of 50.64%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $221.27 which suggests that it could grow by 39.27%. Given that AtriCure, Inc. has higher upside potential than iRhythm Holdings, Inc., analysts believe AtriCure, Inc. is more attractive than iRhythm Holdings, Inc..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $140.5M, which are smaller than iRhythm Holdings, Inc. quarterly revenues of $192.9M. AtriCure, Inc.'s net income of $1.8M is higher than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 2.89x versus 7.19x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 1.25% compared to AtriCure, Inc.'s net margin of 27.89%. AtriCure, Inc.'s return on equity of -2.44% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

AtriCure, Inc. has a consensus price target of $48.78, signalling upside risk potential of 50.64%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.48%. Given that AtriCure, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe AtriCure, Inc. is more attractive than Intuitive Surgical, Inc..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $140.5M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. AtriCure, Inc.'s net income of $1.8M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 63.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 2.89x versus 18.00x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 1.25% compared to AtriCure, Inc.'s net margin of 12.96%. AtriCure, Inc.'s return on equity of -2.44% beat Insulet Corp.'s return on equity of 17.89%.

AtriCure, Inc. has a consensus price target of $48.78, signalling upside risk potential of 50.64%. On the other hand Insulet Corp. has an analysts' consensus of $357.00 which suggests that it could grow by 43.32%. Given that AtriCure, Inc. has higher upside potential than Insulet Corp., analysts believe AtriCure, Inc. is more attractive than Insulet Corp..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.175%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $140.5M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. AtriCure, Inc.'s net income of $1.8M is lower than Insulet Corp.'s net income of $101.6M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 71.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 2.89x versus 6.58x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.